Federal appeals court affirms Amgen’s Otezla patent for five more years

A US appeals court has given Amgen more time to profit off its psoriasis and psoriatic arthritis blockbuster Otezla — with five more years until generics makers Sandoz and Zydus can enter Amgen’s stomping grounds. The US Court of Appeals for the Federal Circuit handed down the ruling Wednesday evening,…